Feldan Therapeutics ǀ Feldan Thérapeutiques

Feldan Therapeutics is a biotechnology company that has been on the cutting edge since its establishment in 2007. The company has developed a patented peptide technology platform known as the Feldan Shuttle, allowing for fast and secure intracellular delivery. The company's mission is to leverage this groundbreaking platform to develop innovative therapeutic applications, as demonstrated by its robust clinical program pipeline. This pipeline harnesses the unique capabilities of the Shuttle to advance treatment options for a range of medical conditions. In June 13, 2023, Feldan Therapeutics secured a significant $16.50M Series B investment led by prominent investors including Amgen Ventures, GC Pharma, Investissement Québec, GC Cell, and FSIT2. This substantial investment not only underscores the confidence of these key players in the company's potential but also provides vital financial resources to drive further research, development, and commercialization efforts. Overall, Feldan Therapeutics stands out as a promising player in the biotechnology industry, with its proprietary technology and strong investor support laying a solid foundation for future growth and success.